As some are now calling it, the greater Philadelphia region, or ‘Cellecon Valley, is garnering a lot of attention these days as a rapidly emerging Biopharma cluster, earning a defining spot among the top 10 clusters in the US.
At BioBuzz, we’ve written extensively about the promise of cell and gene therapeutics for both patients and the companies developing these revolutionary personalized medicines.
2020 was a year like no other for BioHealth Capital Region (BCHR) biotechs, and this year is expected to bring substantial growth across many sectors.
Duchenne Muscular Dystrophy is a severe degenerative muscle disease that impacts about one in 5,000 boys per year across the globe. The disease causes a progressive loss of muscle strength attributable to a loss of a protein called dystrophin, which normally protects muscle fibers from breaking down.
2020 found the United States embroiled in a chaotic political environment, reckoning with social unrest and racial injustice, and voting in one of the most consequential presidential elections in the country’s history.
The COVID-19 Pandemic didn’t stop the Maryland Tech Council from holding their 32nd Annual Industry awards. Taking this event online, MTC continued via a live virtual broadcast to recognize the top Life Sciences and Tech Companies in Maryland.
The BioHealth Capital Region (BHCR) is known globally as a leading vaccine hub with nearly 20% of the world’s leading vaccine development influencers in Maryland, which is the heart of the BHCR.
Five Biotechs Poised to Advance Their Rare Disease Programs in 2020 On the cusp of rare disease month, we’re checking in with Maryland biotech companies at the forefront of rare [….]
Top 10 Biotech News Stories from 2019 from the BioHealth Capital Region on biobuzz.io
Why The Next Biotech Boom Could be Sparked by New Therapies for Neurological Disorders Several Maryland Biotech Firms Are Blazing New Trails in Gene Therapy, Drugs and Diagnostics for Neurological [….]
